MedTrace Logo

A Safety and Efficacy Study of Bacopa Monnieri and Nardostachys Jatamansi to Treat Schizophrenia

NCT00483964 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2007-10-10

No results posted yet for this study

Summary

The purpose of this study is to determine whether a herbal combination of water based extracts of Bacopa monnieri(BM) and Nardostachys jatamansi(NJ) is effective in the treatment of Schizophrenia.

The working hypothesis for this study is that a herbal combination of BM and NJ will be as effective as modern anti-psychotic drugs, in the treatment of Schizophrenia, and will be safe for long term use.

Conditions

Interventions

DRUG

Bacopa monnieri

DRUG

Nardostachys jatamansi

DRUG

Olanzapine

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • Q.Mundewadi Ayurvedic Research & Charitable Trust

    lead OTHER

Principal Investigators

  • AbdulMubeen A Mundewadi, B.A.M.S. · Q.Mundewadi Ayurvedic Research & Charitable Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Completion
2007-09-30

Countries

  • India

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00483964 on ClinicalTrials.gov